Table 1.

Attributes and measures of AAS Users versus Non-AAS-Using Weightlifters

Attribute/measurea	AAS users N = 10	AAS Nonusers N = 10	Pb
Age, years	42.4 (1.3)	42.6 (2.1)	0.94
Race/ethnicity
Non-Hispanic White	9 (90)	10 (10)	1.0
Hispanic White	1 (10)
Four-year college graduate	4 (40)	8 (80)	0.17
Annual income > $50,000	4 (40)	5 (50)	1.00
Lifetime years of regular weightlifting	20.2 (6.8)	22.4 (9.8)	0.57
Age at first AAS use, yrs	23.4 (5.1)	-
Cumulative lifetime AAS use, weeks	482 (582)	-
Cumulative lifetime AAS dose, mgc	704,000 (537,000)	-
Average weekly AAS dose, mgc	1460 (620)
Maximum weekly AAS dose, mgc	2300 (1230)
Use of injectable AAS, as percent of total use	80 (18)
Time since last AAS use:
Current use	4 (40)	-
2–4 months	2 (20)	-
> 20 months	4 (40)	-
Current psychoactive medication use:d
Opioids	3	0
Selective serotonin reuptake inhibitors	2	2
Other psychoactive medications	4	1
Illicit drug use in past 24 hours:
Cocaine	1	0
Cannabis	0	1
Current use of any psychoactive substance	5	3
Cognitive test results:
NAART35 score	15.7 (7.6)e	17.1 (7.7)	0.69
Pattern Recognition Memory, total errors	1.5 (0, 4.25)	2.5 (2.0, 4.25)	0.38
Paired Associates Learning, 6-box errors	5.0 (2.0, 9.5)	2.0 (1.5, 4.75)	0.053
Paired Associates Learning, 8-box errors	29.5 (4.75, 34.25)	10 (17, 22.25)	0.14

^aDemographic attributes and NAART35 scores shown as mean (SD) for continuous variables and as N (%) for ordinal variables; cognitive test results are shown as median (interquartile range).

^bSee text for details of statistical methods.

^cExpressed as mg of testosterone equivalent, calculated as in previous studies (Pope & Katz, 1994).

^dNote that participants could be counted in more than one category (e.g. a participant could be using both opioids and selective serotonin reuptake inhibitors).

^eExcludes one AAS user who was not a native speaker of English.